Is 60 Degrees Pharmaceuticals Inc (SXTP) Stock a Good Investment?
Learn more about 60 Degrees Pharmaceuticals Inc's (SXTP) stock grades for Growth and determine whether this Pharmaceuticals stock meets your investment needs.Jenna Brashear
Stock Evaluator: 60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals, Inc. SXTP
$1.17
-0.08
-6.40%
July 31, 2026 4:00:00 PM
EST
Volume: 153,926
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.
Commentary & Analysis
Financial Summary
| Share Statistics | SXTP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.3 | $569.9 | 2% |
|
| Shares Out (Mil) | 1.7 | 44.8 | 7% |
|
| Institutional Ownership | 92.7% | 84.6% | 62% |
|
| Float (Mil) | 1.8 | 45.1 | 5% |
|
| Beta | 2.70 | 0.67 | 97% |
|
| Avg Daily Volume (000s) | 135 | 294 | 39% |
|
| Price Change (52-week) |
(76.6%) | 65.2% | 8% |
|
| Growth | SXTP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (10.9%) | 6.7% | 5% |
|
| Net Income (5yr) | (19.8%) | (2.0%) | 20% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.890) | ($3.450) | ($3.580) | |
| Month Ago EPS | ($0.890) | ($3.450) | ($3.580) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.780) | ($3.180) | na | |
| Year/Year Chg | (30.6%) | (70.6%) | (94.9%) | |
| Financials | SXTP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $230 | 2% |
|
| Net Income (TTM) (Mil) | ($8) | ($11) | 31% |
|
| EPS (TTM) | ($7.916) | ($0.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($6) | 21% |
|
| Net Cash Flow (TTM) (Mil) | $-0 | $4 | 43% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 10% |
|
| Enterprise Value (Q1) (Mil) | $10 | $493 | 8% |
|
| Valuation | SXTP | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.89 | na |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SXTP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (113.8%) | 65.9% | 2% |
|
| Net Margin | (576.3%) | (0.2%) | 1% |
|
| ROA | (118.9%) | (25.5%) | 5% |
|
| ROE | 148.7% | (21.4%) | 97% |
|
| Liabilities to Assets | 29.9% | 35.5% | 21% |
|
| F-Score | 4 | 3 | 34% |
|
60 Degrees Pharmaceuticals, Inc. did not pass any screens on 7/30/2026.
